GO
| HSI1 | 26,545.10 | +0.25 | 376.81B |
| HSCEI1 | 9,472.35 | +15.83 | 129.31B |
| Back Zoom + Zoom - Block Traded | |
|
HENGRUI PHARMA Receives CN Approval for SHR-1139 Injection Clinical Trial
2025-09-18 17:35:06 HENGRUI PHARMA (01276.HK) announced that its subsidiary, Guangdong Hengrui Pharmaceutical Co., Ltd. (literal translation of "廣東恆瑞醫藥有限公司"), had received an approval from China's National Medical Products Administration for the SHR-1139 injection clinical trials, which are set to commence soon. SHR-1139 injection is a therapeutic biologic independently developed by the company, which is expected to used for the treatment of ulcerative colitis. ~ AAStocks Financial News Web Site: www.aastocks.com | |